Head and Neck Cancer

PV QA 2 - Poster Viewing Q&A 2

MO_34_2808 - Comparison of the Clinical Behaviour of N3 HPV Related and Unrelated Head and Neck Cancer in the IMRT era

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Comparison of the Clinical Behaviour of N3 HPV Related and Unrelated Head and Neck Cancer in the IMRT era
N. T. A. Nguyen1, E. Tran2, J. N. Waldron3, J. Su4, W. Xu5, E. Yu6, J. Kim3, J. G. Ringash7, A. J. Bayley3, A. J. Hope3, M. E. Giuliani3, J. Cho3, S. V. Bratman3, A. Hansen8, J. de Almeida9, J. Irish10, B. Perez-Ordonez11, I. Weinreb11, B. O'Sullivan3, and S. H. Huang3; 1Department of Radiation Oncology, Princess Margaret Cancer Centre- University of Toronto, Toronto, ON, Canada, 2Radiation Oncology- BC Cancer Agency, Vancouver, BC, Canada, 3Department of Radiation Oncology, Princess Margaret Cancer Centre-University of Toronto, Toronto, ON, Canada, 4Division of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Department of Medical Imaging, Princess Margaret Cancer Centre-University of Toronto, Toronto, ON, Canada, 7Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, 8Department of Medical Oncology, Princess Margaret Cancer Centre-University of Toronto, Toronto, ON, Canada, 9Department of Otolaryngology - Head & Neck Surgery, University Health Network- University of Toronto, Toronto, ON, Canada, 10Department of Otolaryngology - Head & Neck Surgery, University Health Network-University of Toronto, Toronto, ON, Canada, 11Surgical Pathology, University Health Network-University of Toronto, Toronto, ON, Canada

Purpose/Objective(s): N3 disease is accepted as having grave prognosis in all forms of head and neck cancer (HNC). We wished to compare clinical presentation, radiological nodal response, and neck outcome after definitive IMRT in N3 HPV-related (HPV+) vs -unrelated (HPV–) HNC.

Materials/Methods: We retrospectively reviewed all N3 HNCs undergoing definitive IMRT ± chemotherapy from 2005-2015. HPV status was tested by p16 staining for all oropharyngeal cancers (OPC) and cancer of unknown primary (CUP). HPV untested laryngo-hypopharyngeal cancer (LHC) were considered HPV–. Clinical presentation, radiological complete response [CR, i.e. Lymph node (LN) ≤ 1.0 cm] at 8-12 weeks following IMRT, and oncologic outcomes were compared between HPV+ vs HPV– cohorts. Multivariable analyses (MVA) identified prognostic factors for regional failure (RF).

Results: Of 129 consecutive N3 HNC, HPV status was ascertained in 119 (92%) revealing 66 HPV+ (OPC/CUP: 65, LHC: 1) and 53 HPV– (OPC/CUP: 29, LHC: 24) cases. Compared to HPV–, HPV+ patients (pts) were younger (median 58 vs 62 years. p=0.006), had fewer smoking pack-years (median 14.5 vs 40 p<0.001), but similar proportions of T3-4 disease (47% vs 39%, p=0.48). HPV+ LNs were more often cystic (41% vs 23%, p=0.049), non-conglomerate (23% vs 8%, p=0.04), and had less skin invasion (30% vs 51% p=0.025) or carotid encasement (21% vs 42%, p=0.02). Rates of retropharyngeal LNs (38% vs 27%, p=0.11), bilateral LNs (45% vs 43%, p=0.85), necrotic LNs (85% vs 89%, p=0.60) and radiological extranodal extension (64% vs 64%, p>0.99) were similar. Concurrent systemic treatment was given in 83% HPV+ vs 57% HPV– (p=0.006). More HPV+ N3 achieved radiological CR (44% vs 25%, p=0.034). Post-IMRT neck dissection (PRND) was negative in all 3 CRs (HPV+ 2; HPV– 1) but positive in 5/19 (26%) HPV+ and 7/13 (58%) HPV– non-CRs (p=0.15). Median follow-up was 4.6 years. RF occurred in 36 (HPV+ 11, HPV– 25). No CR without PRND pts (HPV+: 27, HPV–: 12) had isolated RF. HPV+ pts had higher 3-year overall survival (67% vs 28%, p<0.001), local control (97% vs 85%, p=0.021), and regional control (RC) (85% vs 53%, p=0.021) but similar distant control (77% vs 60%, p=0.078). HPV– non-CR pts had lower 3-year RC vs CRs (43% vs 85%, p=0.01) and was marginally lower in HPV+ (76% vs 96%, p=0.05). No significant difference in 3-year RC was evident in CR pts by HPV status (96% vs 85%, p=0.44). Presence of post-IMRT necrotic LNs (HR 2.8, 95% CI 1.2-6.6, p=0.02) carried a higher RF risk in MVA.

Conclusion: This study shows that HPV+ N3 HNC has unique clinical presentation (less dermal involvement and degree of carotid encasement) and outcomes, relative to HPV– HNC pts. CR is achievable in nearly half the HPV+ and a quarter of HPV- cases with IMRT. Although the sample size is small, pts with CR appear to have good RC in both cohorts. This suggests that careful surveillance is a reasonable option for those with CR. Presence of post-IMRT necrotic LN carries a higher RF risk.

Author Disclosure: N.A. Nguyen: None. E. Tran: None. J.N. Waldron: None. J. Su: None. A.J. Hope: Travel Expenses; Elekta, Inc. M.E. Giuliani: Honoraria; Elekta Inc. Travel Expenses; Elekta Inc. Chair, Education Committee; Canadian Association of Radiation Oncology. J. Cho: None. A. Hansen: None. J. de Almeida: None. J. Irish: None. B. Perez-Ordonez: None. B. O'Sullivan: Partner; University of Toronto. Chair, Prognostic Factors Task Force, TNM Committe; Union for International Cancer Control (UICC).

Send Email for Nhu Tram Nguyen


Assets

MO_34_2808 - Comparison of the Clinical Behaviour of N3 HPV Related and Unrelated Head and Neck Cancer in the IMRT era



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Comparison of the Clinical Behaviour of N3 HPV Related and Unrelated Head and Neck Cancer in the IMRT era